[Public Notice+] Cellivery Successfully Registers US Patent for Genome Regulation System

[Asia Economy Reporter Hyunseok Yoo] Cellivery announced on the 25th that its cell and tissue-permeable genome regulation system, iCP-Cre, has successfully been registered as a patent in the United States.

iCP-Cre enables functionality throughout the entire organism or in specific organs simply through injection. It can selectively remove or insert specific genes in the genome under desired disease conditions and environments, directly revealing whether the proteins expressed by these genes are correlated with particular diseases. According to the company, this is an advanced biotechnology that can enable new drug development.

Additionally, it can eliminate genes encoding proteins that directly cause diseases from the body or, conversely, artificially introduce genes encoding proteins with therapeutic effects. It is a genome regulation system that can realize gene therapy, cell therapy, and even stem cell therapy.

Currently, mass production of iCP-NI is underway, and clinical preparations are being conducted under contracts with one major university hospital in Korea and one tertiary hospital located in Seoul.

The company explained that COVID-19 is a severe sepsis caused by an excessive expression of inflammatory cytokines triggered by the strong immune response to the novel coronavirus, an RNA virus with high infectivity. A company representative stated, “We are currently exchanging opinions with multiple Chinese pharmaceutical companies, including fast-track clinical trials. The main topics of discussion are the relationship between iCP-NI and COVID-19, pharmacotoxicity, pharmacological efficacy, production processes, and production efficiency, so no decisions have been made yet.”

This content was produced with the assistance of AI translation services.